Mark Kowalski
Hoofd Techniek/Wetenschap/O&O bij EUPRAXIA PHARMACEUTICALS INC.
Vermogen: 21 680 $ op 31-05-2024
Actieve functies van Mark Kowalski
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
EUPRAXIA PHARMACEUTICALS INC. | Hoofd Techniek/Wetenschap/O&O | 18-05-2023 | - |
Loopbaan van Mark Kowalski
Eerdere bekende functies van Mark Kowalski
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SIERRA ONCOLOGY, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2017 | 10-03-2022 |
ARBUTUS BIOPHARMA CORPORATION | Hoofd Techniek/Wetenschap/O&O | 12-08-2013 | 30-09-2016 |
Viventia Bio, Inc.
Viventia Bio, Inc. BiotechnologyHealth Technology Viventia Bio, Inc. operates as a biologics oncology company, which focuses on designing, engineering, and developing targeted protein therapeutics. The company was founded by Leslie Lewis Dan in October 2012 and is headquartered in Winnipeg, Canada. | Hoofd Techniek/Wetenschap/O&O | - | - |
AAIPharma, Inc.
AAIPharma, Inc. Miscellaneous Commercial ServicesCommercial Services AAIPharma, Inc. provides product development services to the pharmaceutical, biotechnology and medical device industries. Its services include drug delivery technologies, contract manufacturing, clinical packaging and distribution and bioanalytical services. The company was founded in 1979 and is headquartered in Wilmington, NC. | Hoofd Techniek/Wetenschap/O&O | - | - |
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Hoofd Techniek/Wetenschap/O&O | - | - |
Algemeen Adviseur | - | - | |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Hoofd Techniek/Wetenschap/O&O | 17-01-2011 | - |
Algemeen Adviseur | 17-01-2011 | - |
Opleiding van Mark Kowalski
Rutgers State University of New Jersey | Undergraduate Degree |
University of Kansas Medical School | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 6 |
Canada | 4 |
Verenigd Koninkrijk | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 7 |
General Counsel | 2 |
Undergraduate Degree | 1 |
Sectoraal
Health Technology | 7 |
Consumer Services | 3 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ARBUTUS BIOPHARMA CORPORATION | Health Technology |
EUPRAXIA PHARMACEUTICALS INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Health Technology |
AAIPharma, Inc.
AAIPharma, Inc. Miscellaneous Commercial ServicesCommercial Services AAIPharma, Inc. provides product development services to the pharmaceutical, biotechnology and medical device industries. Its services include drug delivery technologies, contract manufacturing, clinical packaging and distribution and bioanalytical services. The company was founded in 1979 and is headquartered in Wilmington, NC. | Commercial Services |
Viventia Bio, Inc.
Viventia Bio, Inc. BiotechnologyHealth Technology Viventia Bio, Inc. operates as a biologics oncology company, which focuses on designing, engineering, and developing targeted protein therapeutics. The company was founded by Leslie Lewis Dan in October 2012 and is headquartered in Winnipeg, Canada. | Health Technology |
Sierra Oncology, Inc.
Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
- Beurs
- Insiders
- Mark Kowalski
- Ervaring